Marc G. Caron

Marc G. Caron

James B. Duke Professor of Cell Biology

External Address: 
CARL Building Room 487, Durham, NC 27710
Internal Office Address: 
Duke Box 3287, Durham, NC 27710
Phone: 
919.684.5433

Overview

Studies of the mechanisms of action and regulation of hormones and neurotransmitters at the cellular and molecular levels constitute the main goals our of research activities. G protein-coupled receptors (GPCR) mediate the actions of signaling molecules from unicellular organisms to man. We have used adrenergic and dopamine receptors to characterize the structure/function and regulation mechanisms of these prototypes of G protein-coupled receptors. Another approach has been to characterize the nature of neurotransmitter transporters for dopamine, serotonin and other neurotransmitters in an attempt to understand their function in normal and pathological neurotransmission. Another goal of our laboratory is to define the genes and pathways involved in the reinforcing properties of drugs of abuse using both forward and reverse genetic approaches. Our laboratory uses biochemical, molecular biology and gene targeting approaches to examine these questions.

Education & Training

  • Ph.D., University of Miami 1973

Selected Grants

Neurobiology Training Program awarded by National Institutes of Health (Mentor). 2019 to 2024

Mechanistic studies of Mas receptor activation and its role in aortic aneurysm formation awarded by National Institutes of Health (Collaborator). 2017 to 2022

Duke Training Grant in Nephrology awarded by National Institutes of Health (Preceptor). 1995 to 2022

Exploiting Dopamine Receptor Functional Selectivity as an Approach to Treat Parkinson's Symptoms awarded by National Institutes of Health (Principal Investigator). 2017 to 2022

Translational Research in Surgical Oncology awarded by National Institutes of Health (Mentor). 2002 to 2021

Translational Research in Surgical Oncology awarded by National Institutes of Health (Mentor). 2002 to 2021

How Does Huntingtin Control Synaptic Development? awarded by National Institutes of Health (Co-Mentor). 2018 to 2021

How Does Huntingtin Control Synaptic Development? awarded by National Institutes of Health (Co-Mentor). 2018 to 2021

Leveraging Functional Selectivity in the Neurotensin Receptor 1-Mediated Treatment of Addiction awarded by National Institutes of Health (Mentor). 2019 to 2021

Pages

Lefkowitz, R. J., et al. Biochemical mechanisms for regulation of β adrenergic receptors by β adrenergic agonists. Vol. No. 402, 1977, pp. 502–06.

Caron, M. G., and R. R. Gainetdinov. “Role of Dopamine Transporters in Neuronal Homeostasis.” Dopamine Handbook, 2010. Scopus, doi:10.1093/acprof:oso/9780195373035.003.0007. Full Text

Laakso, A., and M. G. Caron. “Dopamine Receptors.” Primer on the Autonomic Nervous System: Second Edition, 2004, pp. 39–43. Scopus, doi:10.1016/B978-012589762-4/50010-4. Full Text

Jacobsen, Jacob P. R., et al. “Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept..” Neuropsychopharmacology, vol. 44, no. 12, Nov. 2019, pp. 2082–90. Pubmed, doi:10.1038/s41386-019-0400-1. Full Text

Martini, Michael L., et al. “Designing Functionally Selective Noncatechol Dopamine D1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity..” Acs Chem Neurosci, vol. 10, no. 9, Sept. 2019, pp. 4160–82. Pubmed, doi:10.1021/acschemneuro.9b00410. Full Text

Pinkerton, Anthony B., et al. “Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators..” J Med Chem, vol. 62, no. 17, Sept. 2019, pp. 8357–63. Pubmed, doi:10.1021/acs.jmedchem.9b00340. Full Text

Israelyan, Narek, et al. “Effects of Serotonin and Slow-Release 5-Hydroxytryptophan on Gastrointestinal Motility in a Mouse Model of Depression..” Gastroenterology, vol. 157, no. 2, Aug. 2019, pp. 507-521.e4. Pubmed, doi:10.1053/j.gastro.2019.04.022. Full Text

Pydi, Sai P., et al. “Adipocyte β-arrestin-2 is essential for maintaining whole body glucose and energy homeostasis..” Nat Commun, vol. 10, no. 1, July 2019. Pubmed, doi:10.1038/s41467-019-11003-4. Full Text

Martini, Michael L., et al. “Defining Structure-Functional Selectivity Relationships (SFSR) for a Class of Non-Catechol Dopamine D1 Receptor Agonists..” J Med Chem, vol. 62, no. 7, Apr. 2019, pp. 3753–72. Pubmed, doi:10.1021/acs.jmedchem.9b00351. Full Text

Mackie, Duncan I., et al. “hCALCRL mutation causes autosomal recessive nonimmune hydrops fetalis with lymphatic dysplasia..” J Exp Med, vol. 215, no. 9, Sept. 2018, pp. 2339–53. Pubmed, doi:10.1084/jem.20180528. Full Text

Pack, Thomas F., et al. “The dopamine D2 receptor can directly recruit and activate GRK2 without G protein activation..” J Biol Chem, vol. 293, no. 16, Apr. 2018, pp. 6161–71. Pubmed, doi:10.1074/jbc.RA117.001300. Full Text

Rose, Samuel J., et al. “Engineered D2R Variants Reveal the Balanced and Biased Contributions of G-Protein and β-Arrestin to Dopamine-Dependent Functions..” Neuropsychopharmacology, vol. 43, no. 5, Apr. 2018, pp. 1164–73. Pubmed, doi:10.1038/npp.2017.254. Full Text

Pages

Lajiness, M. E., et al. “Signaling mechanisms of D2, D3, and D4dopamine receptors determined in transfected cell lines.” Clinical Neuropharmacology, vol. 18, no. SUPPL. 1, 1995. Scopus, doi:10.1097/00002826-199501001-00004. Full Text